Skip to main content
Clinical Trials/NCT05813106
NCT05813106
Recruiting
Phase 4

Effect of Fixed Dose Intravenous Dexmedetomidine on Emergence Delirium After General Anesthesia for a Surgery in Pediatric Patient

Security Forces Hospital1 site in 1 country60 target enrollmentDecember 1, 2022

Overview

Phase
Phase 4
Intervention
Dexmedetomidine Hydrochloride
Conditions
Emergence Delirium
Sponsor
Security Forces Hospital
Enrollment
60
Locations
1
Primary Endpoint
Emergence delirium
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Various pharmacological interventions in peri-operative period have been used in literature to prevent ED which include use of propofol, fentanyl, ketamine, clonidine, midazolam and dexmedetomidine etc (5). Dexmedetomidine is a potent highly selective alpha-2 agonist. Its effect on the receptors in brain results in sedation resembling non-REM sleep with minimal respiratory depression (6). It has been used as continuous infusion or as fixed dose in the range between 0.15 mcg/kg to 2 mcg/kg to prevent ED in children (7, 8, 9). Higher doses result in better prevention of ED at the expense of more hemodynamic disturbances and longer PACU stay (9) while lower doses were not as effective (7). The aim of this study was to investigate the role of fixed dose of 0.2 mcg/kg dexmedetomidine in prevention of emergence delirium in pediatric patients undergoing general anesthesia.

Detailed Description

Emergence delirium (ED) is an altered state of consciousness that usually occurs within 45 minutes after cessation of anesthesia. It typically presents as disorientation, averted eyes or staring, psychomotor agitation and non-purposeful, resistive movements like pulling, kicking or flailing (1, 2). ED can result in potential risk of bodily harm to patient or healthcare staffs, prolonged PACU (post-anesthesia care unit) stay and postoperative maladaptive changes including temper tantrums, attention seeking, sleep alterations and bed wetting in children (2). Risk factors for ED include preoperative anxiety and confusion, psychological immaturity and use of various medications peri-operatively (2, 3). The incidence of ED varies by age of patient, anesthesia technique, type of surgeries, pain and also by choice of tool to diagnose ED. It occurs two to three more commonly in children as compared to adults. Scientific literature suggest the incidence of ED in the range between 20 -80 % in pediatric anesthesia practice (4). Various pharmacological interventions in peri-operative period have been used in literature to prevent ED which include use of propofol, fentanyl, ketamine, clonidine, midazolam and dexmedetomidine etc (5). Dexmedetomidine is a potent highly selective alpha-2 agonist. Its effect on the receptors in brain results in sedation resembling non-REM sleep with minimal respiratory depression (6). It has been used as continuous infusion or as fixed dose in the range between 0.15 mcg/kg to 2 mcg/kg to prevent ED in children (7, 8, 9). Higher doses result in better prevention of ED at the expense of more hemodynamic disturbances and longer PACU stay (9) while lower doses were not as effective (7). The aim of this study was to investigate the role of fixed dose of 0.2 mcg/kg dexmedetomidine in prevention of emergence delirium in pediatric patients undergoing general anesthesia.

Registry
clinicaltrials.gov
Start Date
December 1, 2022
End Date
April 30, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Anwar ul Huda

Doctor

Security Forces Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients aged between 2 and 12 years, scheduled to undergo general anesthesia for a surgery with an ASA score of 1 to 3 will be included in the study.

Exclusion Criteria

  • Parents who refused enrollment or later requested removal for the study, those who are unable to give informed consent and patients with known allergy to dexmedetomidine, psychiatric disorders or use of psychiatric medications will not be included in the study

Arms & Interventions

Dexmedetomidine group

These patients will receive 0.2 mcg/kg dexmedetomidine intravenously 30 minutes before end

Intervention: Dexmedetomidine Hydrochloride

Control group

These patients will receive normal saline intravenously 30 minutes before end

Intervention: normal saline

Outcomes

Primary Outcomes

Emergence delirium

Time Frame: up to 120 minutes

Emergence delirium will be measured using PAED score

Secondary Outcomes

  • Side effects(PACU stay maximum 120 minutes)
  • Pain score(every 15 minutes upto discharge from PACU maximum 120 minutes)
  • Opioid consumption(upto discharge from PACU maximum 120 minutes)

Study Sites (1)

Loading locations...

Similar Trials